DocWire News Editors

DocwireNews

Irritable bowel syndrome with predominant constipation (IBS-C) is a complex disorder that has a large economic effect on healthcare systems and society, according to the results of an economic study published in BMC Gastroenterology. This economic impact highlights a need for greater understanding of patients with severe IBS-C, and a move away from a one-size-fits-all approach.&ldquo;Given the symptom and severity complexities of IBS-C there is a notable paucity of information related to health economic burden and resource utilization, especially in sufferers at the more severe end of the severity spectrum,&rdquo; explained study researcher Jan Tack, of the University Hospital Gasthuisberg, Leuven, Belgium, and colleagues. &ldquo;Newer agents approved to treat IBS-C may potentially decrease the need for frequent visits to physicians and multiple medications, possibly translating into lower healthcare utilization and drug-related costs.&rdquo;To study these things, Tack and colleagues conducted a 1-year retrospective-prospective study of 525 patients diagnosed with IBS-C in the last 5 years with moderate to severe disease at inclusion. Patients were from six different European countries.Baseline and retrospective data were obtained from medical records and patient interviews. IBS symptom severity scores (SSS) were obtained at baseline and 6 months. Sixty-percent of included patients has severe IBS-C.During the follow-up period, between 11.1% and 24.0% of patients were hospitalized or had an emergency department visit, with a median stay of between 1.5 and 12.0 days. Additionally, between 41.1% and 90.4% of patients took prescription drugs because of their disorders.IBS-C also resulted in missed worked. Between almost one-quarter to one-half (21.4% to 50.8%) of employed patients had to take sick leave from work.&ldquo;Overall, patients in this cohort reported a high frequency of symptoms that led to substantial direct and indirect costs for healthcare systems and society,&rdquo; the researchers wrote.The researchers calculated that the mean annual direct cost to the healthcare system of these patients was between &euro;937.1 to &euro;2,108.0 (~$1,043 to $2,347.14). The total direct cost for the healthcare system and patients combined was &euro;1,421.7 to &euro;2,487.1 (~$1,582.98 to $2,769.25). Hospitalizations and emergency department visits were the largest cost driver, according to the study.&ldquo;Costs attributable to hospitalizations/ER visits in this study were higher than that reported for IBS patients in general,&rdquo; the researchers wrote. &ldquo;This finding is related to the predominantly severe IBS-C population of this study and suggests that patients with more severe IBS-C may require more inpatient care.&rdquo;Tack J, Stanghellini V, Mearin F, et al. Economic burden of moderate to severe irritable bowel syndrome with constipation in six European countries. BMC Gastroenterol. 2019;19:69. Doi:10.1186/s12876-019-0985-1.&nbsp;

Areef Ishani, MD

Joel M. Topf, MD, FACP

Kidney Stones With Chlorthalidone Versus Hydrochlorothiazide

NKF Spring Clinical Meetings 2025

MarkAlain Déry, DO

Eric Griggs, MD

Measles in America: An Ongoing Problem

Infectious Disease

Roger Rodby, MD

Seldin Award Winner Advocates Online Education

Latest News

IBS with Constipation Has Large Economic Effect on Healthcare Systems, Patients

Gastroenterology

Irritable bowel syndrome with predominant constipation (IBS-C) is a complex disorder that has a large economic effect on healthcare systems and society, according to the ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe